Author

M. P. Rettig

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:host-pathogen & immune response· 2 Approach:statistical model· 2

Frequent Co-Authors

J. F. DiPersio· 5 shared E. Chendamarai· 2 shared J. K. Ritchey· 2 shared S. P. Persaud· 2 shared A. A. Desai· 1 shared A. Arruda· 1 shared A. Asnani· 1 shared A. Cesano· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

J. F. DiPersio

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation

A. R. Yelamali, E. Chendamarai, J. K. Ritchey, M. P. Rettig, J. F. DiPersio, S. P. Persaud

This paper develops a streptavidin-drug conjugate platform to efficiently optimize antibody-based conditioning for HSCT, finding that PBD dimer SGD-1882 is most effective for targeting HSCs and AML cells.

bioRxiv · Feb 12, 2024Immunology

Immunosuppression and Outcomes in Acute Myeloid Leukemia

F. Ferraro, C. Miller, K. Christensen, N. M. Helton, M. O'Laughlin, C. C. Fronick, R. S. Fulton, J. Kohlschmidt, A.-K. Eisfeld, C. D. Bloomfield, S. M. Ramakrishnan, R. B. Day, L. D. Wartman, G. L. Uy, J. S. Welch, , T. J. Ley

This study identifies immunosuppressive features in AML cells associated with poor outcomes in patients treated with standard chemotherapy.

bioRxiv · Sep 3, 2021 · PreprintCancer Biology

Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury

Z. Guo, C. Valenzuela Ripoll, A. Picataggi, D. R. Rawnsley, M. Ozcan, J. A. Chirinos, E. Chendamarai, A. Girardi, T. Riehl, H. Evie, A. Diab, A. Kovacs, K. Hyrc, X. Ma, A. Asnani, , A. Javaheri

This paper investigates the role of apolipoprotein M in anthracycline cardiotoxicity, finding that ApoM protects against cardiac dysfunction and lysosomal injury through the autophagy-lysosome pathway.

bioRxiv · Jan 12, 2021Pharmacology & Toxicology

Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation

S. P. Persaud, J. K. Ritchey, J. Choi, P. G. Ruminski, M. L. Cooper, M. P. Rettig, J. F. DiPersio

This study shows that combining CD45-targeted ADCs with baricitinib enables effective allogeneic HSCT with high donor chimerism and reduced graft-versus-host disease.

bioRxiv · Oct 2, 2020Immunology

Immune Landscapes Predict Chemotherapy Resistance And Immunotherapy Response In Acute Myeloid Leukemia

J. Vadakekolathu, M. D. Minden, T. Hood, S. E. Church, S. Reeder, H. Altmann, A. H. Sullivan, E. J. Viboch, T. Patel, N. Ibrahimova, S. E. Warren, A. Arruda, Y. Liang, J. Muth, M. Schmitz, , S. Rutella

This study identifies immune subtypes in AML and shows that IFN-gamma profiles predict chemotherapy resistance and immunotherapy response.

bioRxiv · Jul 26, 2019Immunology